vs

Side-by-side financial comparison of Babcock & Wilcox Enterprises, Inc. (BW) and CareDx, Inc. (CDNA). Click either name above to swap in a different company.

CareDx, Inc. is the larger business by last-quarter revenue ($117.7M vs $113.4M, roughly 1.0× Babcock & Wilcox Enterprises, Inc.). On growth, CareDx, Inc. posted the faster year-over-year revenue change (39.0% vs 0.6%). CareDx, Inc. produced more free cash flow last quarter ($514.0K vs $-7.2M). Over the past eight quarters, CareDx, Inc.'s revenue compounded faster (12.9% CAGR vs -16.9%).

Babcock & Wilcox Enterprises, Inc. is an American energy technology and service provider that is active and has operations in many international markets with its headquarters in Akron, Ohio. Historically, the company is best known for their steam boilers.

CareDx, Inc. is a leading precision medicine company dedicated to organ transplant patient care. It develops and commercializes diagnostic tests for rejection surveillance, digital health management tools, and supportive clinical services, catering to transplant clinicians, patients, and healthcare systems across North America and European core markets.

BW vs CDNA — Head-to-Head

Bigger by revenue
CDNA
CDNA
1.0× larger
CDNA
$117.7M
$113.4M
BW
Growing faster (revenue YoY)
CDNA
CDNA
+38.4% gap
CDNA
39.0%
0.6%
BW
More free cash flow
CDNA
CDNA
$7.7M more FCF
CDNA
$514.0K
$-7.2M
BW
Faster 2-yr revenue CAGR
CDNA
CDNA
Annualised
CDNA
12.9%
-16.9%
BW

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
BW
BW
CDNA
CDNA
Revenue
$113.4M
$117.7M
Net Profit
$2.8M
Gross Margin
20.6%
Operating Margin
0.2%
1.0%
Net Margin
2.4%
Revenue YoY
0.6%
39.0%
Net Profit YoY
EPS (diluted)
$0.11
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BW
BW
CDNA
CDNA
Q1 26
$117.7M
Q4 25
$113.4M
$108.4M
Q3 25
$149.0M
$100.1M
Q2 25
$144.1M
$86.7M
Q1 25
$181.2M
$84.7M
Q4 24
$112.7M
$86.6M
Q3 24
$152.6M
$82.9M
Q2 24
$151.4M
$92.3M
Net Profit
BW
BW
CDNA
CDNA
Q1 26
$2.8M
Q4 25
$-4.1M
Q3 25
$35.1M
$1.7M
Q2 25
$-58.5M
$-8.6M
Q1 25
$-22.0M
$-10.4M
Q4 24
$-63.1M
$87.7M
Q3 24
$-5.3M
$-10.6M
Q2 24
$25.4M
$-4.6M
Gross Margin
BW
BW
CDNA
CDNA
Q1 26
Q4 25
20.6%
Q3 25
24.9%
Q2 25
30.0%
Q1 25
22.1%
Q4 24
16.7%
Q3 24
23.7%
Q2 24
21.8%
Operating Margin
BW
BW
CDNA
CDNA
Q1 26
1.0%
Q4 25
0.2%
-5.6%
Q3 25
4.4%
-0.2%
Q2 25
5.6%
-12.8%
Q1 25
3.2%
-15.8%
Q4 24
-8.1%
97.5%
Q3 24
1.0%
-16.6%
Q2 24
-2.9%
-7.9%
Net Margin
BW
BW
CDNA
CDNA
Q1 26
2.4%
Q4 25
-3.8%
Q3 25
23.5%
1.7%
Q2 25
-40.6%
-9.9%
Q1 25
-12.1%
-12.2%
Q4 24
-56.0%
101.3%
Q3 24
-3.5%
-12.8%
Q2 24
16.8%
-5.0%
EPS (diluted)
BW
BW
CDNA
CDNA
Q1 26
$0.05
Q4 25
$0.11
$-0.08
Q3 25
$0.30
$0.03
Q2 25
$-0.63
$-0.16
Q1 25
$-0.26
$-0.19
Q4 24
$-0.73
$1.60
Q3 24
$-0.10
$-0.20
Q2 24
$0.24
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BW
BW
CDNA
CDNA
Cash + ST InvestmentsLiquidity on hand
$89.5M
$77.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$-131.5M
Total Assets
$662.9M
$411.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BW
BW
CDNA
CDNA
Q1 26
$77.9M
Q4 25
$89.5M
$177.2M
Q3 25
$25.2M
$194.2M
Q2 25
$23.4M
$186.3M
Q1 25
$23.5M
$230.9M
Q4 24
$26.9M
$260.7M
Q3 24
$30.6M
$240.9M
Q2 24
$95.5M
$228.9M
Total Debt
BW
BW
CDNA
CDNA
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$0
Q2 24
$0
Stockholders' Equity
BW
BW
CDNA
CDNA
Q1 26
Q4 25
$-131.5M
$303.1M
Q3 25
$-232.2M
$311.1M
Q2 25
$-309.2M
$327.4M
Q1 25
$-303.0M
$379.3M
Q4 24
$-283.8M
$378.4M
Q3 24
$-203.7M
$273.2M
Q2 24
$-198.9M
$264.7M
Total Assets
BW
BW
CDNA
CDNA
Q1 26
$411.1M
Q4 25
$662.9M
$413.2M
Q3 25
$657.9M
$432.3M
Q2 25
$703.5M
$444.3M
Q1 25
$719.7M
$489.6M
Q4 24
$727.0M
$491.1M
Q3 24
$804.6M
$477.0M
Q2 24
$849.1M
$466.8M
Debt / Equity
BW
BW
CDNA
CDNA
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.00×
Q2 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BW
BW
CDNA
CDNA
Operating Cash FlowLast quarter
$-3.0M
$4.3M
Free Cash FlowOCF − Capex
$-7.2M
$514.0K
FCF MarginFCF / Revenue
-6.3%
0.4%
Capex IntensityCapex / Revenue
3.7%
Cash ConversionOCF / Net Profit
1.54×
TTM Free Cash FlowTrailing 4 quarters
$-85.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BW
BW
CDNA
CDNA
Q1 26
$4.3M
Q4 25
$-3.0M
$21.4M
Q3 25
$-32.1M
$37.4M
Q2 25
$-25.3M
$9.9M
Q1 25
$-8.5M
$-26.6M
Q4 24
$-22.5M
$21.9M
Q3 24
$-69.5M
$12.5M
Q2 24
$-11.8M
$18.9M
Free Cash Flow
BW
BW
CDNA
CDNA
Q1 26
$514.0K
Q4 25
$-7.2M
Q3 25
$-37.6M
Q2 25
$-28.1M
Q1 25
$-12.8M
Q4 24
$-23.6M
Q3 24
$-71.6M
Q2 24
$-16.4M
FCF Margin
BW
BW
CDNA
CDNA
Q1 26
0.4%
Q4 25
-6.3%
Q3 25
-25.3%
Q2 25
-19.5%
Q1 25
-7.1%
Q4 24
-20.9%
Q3 24
-46.9%
Q2 24
-10.8%
Capex Intensity
BW
BW
CDNA
CDNA
Q1 26
Q4 25
3.7%
Q3 25
3.7%
Q2 25
1.9%
Q1 25
2.4%
Q4 24
1.0%
Q3 24
1.4%
Q2 24
3.0%
Cash Conversion
BW
BW
CDNA
CDNA
Q1 26
1.54×
Q4 25
Q3 25
-0.92×
22.30×
Q2 25
Q1 25
Q4 24
0.25×
Q3 24
Q2 24
-0.46×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BW
BW

Construction$98.8M87%
Other$14.6M13%

CDNA
CDNA

Financial Results Total$85.0M72%
Patient and digital solutions revenue$16.0M14%
Product revenue$10.3M9%
Other$6.4M5%

Related Comparisons